thymidine 5'-triphosphate (TTP)

Subscribe to Selected New Research on thymidine 5'-triphosphate

1812 relevant articles (109 outcomes, 114 trials/studies) found for this Bio-Agent

Description: RN given refers to parent cpd

Also Known As:

TTP; thymidine triphosphate; 2'-deoxythymidine-5'-triphosphate; dTTP; deoxythymidine triphosphate; thymidine 5'-triphosphate, P''-(32)P-labeled; thymidine 5'-triphosphate, magnesium salt; thymidine 5'-triphosphate, trisodium salt; thymidine 5'-(tetrahydrogen triphosphate)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Pyrimidines: 269

Pyrimidine Nucleotides: 25

Thymine Nucleotides: 6

thymidine 5'-triphosphate: 1812

Nucleic Acids, Nucleotides, and Nucleosides: 1

Nucleotides: 2273

Pyrimidine Nucleotides: 25

Thymine Nucleotides: 6

thymidine 5'-triphosphate: 1812

Deoxyribonucleotides: 23

Thymine Nucleotides: 6

thymidine 5'-triphosphate: 1812

Experts

1.	Budde, Ulrich: 2 articles (07/2008 - 09/2004)
2.	Blackshear, Perry J: 2 articles (06/2007 - 02/2004)
3.	Terrell, Deirdra R: 2 articles (01/2004 - 01/2003)
4.	George, James N: 2 articles (01/2004 - 01/2003)
5.	Vesely, Sara K: 2 articles (01/2004 - 01/2003)
6.	Eckardt, Kai-Uwe: 1 article (07/2008)
7.	Jantsch, Jonathan: 1 article (07/2008)
8.	Hagel, Stefan: 1 article (07/2008)
9.	Honsová, E: 1 article (07/2008)
10.	Kalden, Joachim R: 1 article (07/2008)

Related Diseases

1.	Thrombotic Thrombocytopenic Purpura 11/09/1991 - "A controlled multicentre trial was conducted in France over a period of five years in 40 patients with thrombotic thrombocytopenic purpura (TTP) to try to determine the best treatment of this disease" 06/01/2003 - "Thrombotic thrombocytopenic purpura (TTP) is a serious hematologic disorder with a high rate of morbidity and mortality when it fails to go into remission" 05/01/1990 - "The observation of two clinical cases make possible an evaluation of the potential therapeutic activity of platelet function inhibitors in thrombotic thrombocytopenic purpura (TTP)" 01/01/2006 - "New developments in the understanding of thrombotic thrombocytopenic purpura (TTP) provide opportunities for improved patient care" 07/01/1993 - "In this study we evaluated the effect of serum collected from seven thrombotic thrombocytopenic purpura (TTP) patients, either in the acute phase of the disease or in clinical remission, on the in vitro growth of bone marrow haematopoietic progenitor cells, obtained from the same TTP patients in clinical remission and from normal donors" Order ALL the reference details at left...
2.	Neoplasms (Cancer) 11/20/2008 - "RESULTS: The presence of KIT exon 11-mutant genotype (n = 283) correlated with improved treatment outcome when compared with KIT exon 9-mutant (n = 32) and wild-type (WT; n = 67) genotypes for objective response (complete response [CR]/partial response [PR], 71.7% v 44.4% [P = .007]; and 44.6% [P = .0002], respectively); time to tumor progression (TTP; median 24.7 months v 16.7 and 12.8 months, respectively); and overall survival (OS; median 60.0 months v 38.4 and 49.0 months, respectively)" 03/01/1993 - "Patients whose malignant neoplasms were in complete or partial remission at the time of development of C-TTP/HUS had a significantly higher estimated 1-year survival rate (74%) as compared with a historic control group of patients receiving other treatments (22%, P = 0.0161)" 11/01/2005 - "The median remission time was 3.5 months and time to tumor progression (TTP) was 4.5 months" 12/01/2004 - "The time to tumor progression (TTP) was 2 to 18 months (median 5 months), and duration of remission was 4 to 14 months (median 8 months)" 06/01/2008 - "The secondary objectives of the study are to assess the time-to-tumor progression (TTP), defined as time from randomization to date of first documentation of progressive disease (PD), to determine the clinical response (RR), defined as the sum of complete response (CR) and partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST), and to evaluate the safety of the two regimens" Order ALL the reference details at left...
3.	Hemolytic-Uremic Syndrome 05/01/2002 - "STUDY DESIGN AND METHODS: The activities of vWF-CPase and its inhibitor were measured in 27 patients with nonfamilial TTP and hemolytic-uremic syndrome (HUS) to examine the relationship between the clinical variables and vWF-CPase activity" 04/01/2008 - "METHODS: Patient data are from The Oklahoma TTP-hemolytic uremic syndrome (HUS) Registry, an inception cohort of 348 consecutive patients with their first episode of clinically diagnosed TTP or HUS, 1989-2006" 07/01/2007 - "The Oklahoma Thrombotic ThrombocytopenicPurpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry has enrolled all 335 consecutive patients from central, western and southeastern Oklahoma who had their first episode of clinically diagnosed TTP or HUS from 1989 through 2005; follow-up is complete for 333 patients" 01/01/2007 - "PATIENTS AND METHODS: We report the 17-year experience of The Oklahoma TTP-Hemolytic-Uremic Syndrome (HUS) Registry (1989-2005) and a systematic review of previously published case reports" 01/01/2006 - "Levels below 5% are highly specific for TTP basically excluding hemolytic uremic syndrome (HUS)" Order ALL the reference details at left...
4.	Syndrome 07/01/1990 - "All patients improved quickly following this change in therapy, and the TTP syndrome resolved in all seven." 01/01/2008 - "The study demonstrates that while differentiating between HUS and TTP is sometimes difficult, in most cases the two syndromes have quite different predisposing factors and clinical parameters, enabling clinical and epidemiological profiling for these disorders." 01/01/1979 - "The results of this study raise the possibility that TTP may fit within the myeloproliferative category, perhaps representing an acute variant of Di-Guglielmo Syndrome." 08/18/2008 - "CONCLUSIONS: Myocardial injury frequently complicates the TTP syndrome and associated mortality is substantial" 04/01/2008 - "RESULTS AND CONCLUSIONS: The clinical spectrum of syndromes described as TTP is variable with multiple etiologies" Order ALL the reference details at left...
5.	Colorectal Neoplasms (Colorectal Cancer) 06/01/2003 - "CONCLUSION: For patients with metastatic colorectal cancer, second-line treatment with FOLFOX4 is superior to treatment with LVFU2 in terms of RR, TTP, and relief of TRS." 10/10/2007 - "PURPOSE: Our aims were to determine the correlations between progression-free survival (PFS), time to progression (TTP), and response rate (RR) with overall survival (OS) in the first-line treatment of metastatic colorectal cancer (MCRC), and to identify a potential surrogate for OS" 10/01/2008 - "Median OS, TTP, and TTTF for patients with colorectal carcinoma were 357, 112, and 107 days, respectively, versus 638, 118, and 363 days in patients with other metastatic sources" 07/01/2007 - "CONCLUSION: FOLFOX-4 in patients with pretreated colorectal cancer was effective, and contributed to prolonged life with the TTP of 5 months" 02/01/2001 - "PATIENTS AND METHODS: The ratio of TTP during first and second-line therapy, identified as the growth modulation index (GMI), was determined in 34 patients with advanced colorectal cancer" Order ALL the reference details at left...

Related Drugs and Biologics

1.	docetaxel (Taxotere)
2.	Vincristine (Oncovin)
3.	von Willebrand Factor
4.	capecitabine (Xeloda)
5.	bortezomib (Velcade)
6.	Fluorouracil (Carac)
7.	Tamoxifen
8.	Procarbazine (Matulane)
9.	temozolomide (Temodar)
10.	Autoantibodies

Related Therapies and Procedures

1.	Plasma Exchange
2.	Drug Therapy (Chemotherapy)
3.	Splenectomy
4.	Plasmapheresis
5.	Blood Component Removal (Apheresis)

Best Treatments:
Research Summary Report
on Thrombotic Thrombocytopenic Purpura

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 102 Outcomes
Top 200 Key Drugs and Biologics
Top 42 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>